8-K: BioCryst Achieves First-Ever Profitability, Boosts HAE Portfolio

BioCryst Pharmaceuticals reported record full-year 2025 financial results, achieving profitability for the first time, driven by strong ORLADEYO sales and strategic business developments.

Summary

• Full year 2025 ORLADEYO net revenue reached $601.8 million, representing a 38% year-over-year increase (43% excluding European ORLADEYO revenue following its sale).
• The company achieved record GAAP and non-GAAP operating profit for the full year 2025, marking its first-ever full-year profitability.
• Full year 2026 ORLADEYO revenue guidance was maintained between $625 million and $645 million.
• Received FDA approval for ORLADEYO oral pellets for patients with Hereditary Angioedema (HAE) aged 2 to <12 years, making it the first and only targeted oral prophylactic therapy for this pediatric group.
• Completed the acquisition of Astria Therapeutics, Inc. in January 2026, adding navenibart, an injectable, long-acting, monoclonal antibody inhibitor of plasma kallikrein, to its HAE portfolio.
• Navenibart is currently in Phase 3 clinical development, with the program on track to support regulatory filing by the end of 2027.
• New positive, interim results from the long-term ALPHASOLAR trial for navenibart showed sustained HAE attack suppression, with mean and median reductions from baseline of 92% and 97% in the Q3M dosing arm, and 90% and 97% in the Q6M dosing arm.
• A Phase 1 trial of BCX17725, an investigational KLK5 inhibitor for Netherton syndrome, is currently enrolling and dosing patients, with data expected by the end of 2026.
• Total GAAP revenues for full year 2025 were $874.8 million, significantly up from $450.7 million in 2024.
• GAAP operating profit for full year 2025 was $341.0 million, a substantial improvement from an operating loss of $2.5 million in 2024.
• Non-GAAP total revenues were $592.9 million (+45% y-o-y) and non-GAAP operating profit was $214.2 million (+198% y-o-y) for full year 2025.
• Cash, cash equivalents, restricted cash, and investments totaled $337.5 million at December 31, 2025.
• Net cash utilization for the full year 2025 was $5.4 million, with $85.2 million of cash generated when excluding the payoff of the Pharmakon loan and net proceeds from the European ORLADEYO business sale.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, highlighted by the company achieving profitability for the first time, robust ORLADEYO sales growth, and strategic expansion of its HAE portfolio with a promising late-stage asset.

Positives

• Achieved full-year profitability for the first time in company history, with record GAAP and non-GAAP operating profit.
• Strong ORLADEYO net revenue growth of 38% year-over-year, reaching $601.8 million.
• FDA approval of ORLADEYO oral pellets expands the market to younger HAE patients (2 to <12 years old).
• Strategic acquisition of Astria Therapeutics adds navenibart, a late-stage HAE prophylaxis asset, strengthening the HAE portfolio and long-term growth trajectory.
• Positive interim Phase 3 results for navenibart (ALPHASOLAR trial) demonstrated robust HAE attack suppression (90-97% reduction).
• Interest expense decreased by 20% year-over-year to $78.9 million, primarily due to the payoff of the Pharmakon Term Loan.
• Generated $85.2 million of cash in 2025, excluding the impact of the Pharmakon loan payoff and European ORLADEYO business sale.

Negatives

• Incurred a one-time loss on extinguishment of debt of $17.3 million for the full year 2025 due to the payoff of the Pharmakon Term Loan.
• Selling, general and administrative expenses increased significantly, with GAAP S&M up 16% year-over-year and GAAP G&A up 45% year-over-year, driven by commercial progression and headcount growth.

Risks

• BioCryst's ability to successfully progress its pipeline development plans as described, including meeting expected timelines, may be challenged.
• Ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not yield positive results.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results do not necessarily predict final results.
• BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates.
• BioCryst may not advance human clinical trials with product candidates as expected.
• The FDA or other applicable regulatory agencies may require additional studies, delay regulatory clearances, impose restrictions or clinical holds, or withhold, delay, or withdraw market approval for products and product candidates.
• Statements and projections regarding financial guidance and goals may differ from actual results based on market factors and BioCryst's ability to execute its operational and budget plans.
• Actual financial results may not be consistent with expectations, including that revenue, operating expenses, and cash usage may not be within management's expected ranges.

Future Outlook

The company maintained its full year 2026 global net ORLADEYO revenue guidance to be between $625 million and $645 million. Total revenue for full year 2026, including RAPIVAB, is expected to be between $635 million and $660 million. Non-GAAP operating expenses for full year 2026, excluding stock-based compensation, restructuring, and transaction-related costs, are projected to be between $450 million and $470 million. The navenibart Phase 3 program is on track to support regulatory filing by the end of 2027, and data from the BCX17725 Phase 1 program is expected by the end of 2026.

Management Comments

• "2025 was fundamentally transformative for BioCryst. We achieved full-year profitability for the first time in the company's history, driven by strong commercial execution that delivered the highest level of new patient prescriptions in the U.S. since the initial launch of ORLADEYO, even as the treatment landscape continued to evolve." Charlie Gayer, President and Chief Executive Officer.
• "We also advanced key business development initiatives that streamlined our operations and further strengthened our leadership position in hereditary angioedema." Charlie Gayer, President and Chief Executive Officer.
• "We entered 2026 with strong momentum, completing the acquisition of Astria Therapeutics to grow our HAE portfolio to meet the needs of more patients, while adding to our long-term growth trajectory well into the next decade." Charlie Gayer, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that BioCryst's focus on hereditary angioedema (HAE) positions it in a specialized but competitive rare disease market. The acquisition of Astria Therapeutics and its late-stage asset navenibart demonstrates a strategy to consolidate leadership and diversify its HAE portfolio, crucial as the treatment landscape evolves with new therapies. The expansion of ORLADEYO's FDA approval to younger pediatric patients also broadens its market reach within the HAE segment, a key differentiator in a market with high unmet needs.

Comparison to Industry Standards

• The HAE market includes competitors such as Takeda (with CINRYZE, TAKHZYRO) and CSL Behring (with HAEGARDA). BioCryst's ORLADEYO, as the first oral, once-daily plasma kallikrein inhibitor, offers a significant convenience advantage over many injectable therapies.
• Navenibart's Phase 3 development, with potential Q3M and Q6M dosing, aims to compete with other long-acting prophylactic treatments by offering potentially less frequent administration. For example, Takeda's TAKHZYRO (lanadelumab) is typically dosed every two or four weeks.
• The reported 90-97% HAE attack rate reductions for navenibart in the ALPHASOLAR trial are highly competitive and align with or exceed efficacy rates seen in other leading HAE prophylactic treatments, such as TAKHZYRO which demonstrated an 87% reduction in attack rate in its pivotal trial.

Stakeholder Impact

• Shareholders: Positive impact due to the company achieving profitability for the first time, strong revenue growth, expanded product indications, and a strengthened pipeline, which could lead to increased shareholder value.
• Patients (HAE): Positive impact with the FDA approval of ORLADEYO oral pellets for younger children and the advancement of navenibart, offering more treatment options and improved prophylaxis.
• Employees: Potential positive impact from company growth and strategic acquisitions, though workforce reduction costs were mentioned in non-GAAP adjustments for 2025, suggesting some restructuring.
• Customers (Healthcare Providers): Expanded treatment options for HAE patients, including a pediatric formulation and a long-acting injectable, providing more tools for patient management.

Next Steps

• Present navenibart results and other abstracts at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia from February 27 to March 2, 2026.
• Continue enrolling and dosing patients in the Phase 1 trial of BCX17725 for Netherton syndrome.
• Report data from the BCX17725 program in up to 12 patients by the end of 2026.
• Continue the navenibart Phase 3 program (ALPHA-ORBIT and ORBIT-EXPANSE) with regulatory filing targeted by the end of 2027.
• Host a conference call and webcast on February 26, 2026, to discuss the financial results and provide a corporate update.

Key Dates

Recommendation

The company achieved full-year profitability for the first time, driven by significant ORLADEYO revenue growth and strategic business decisions like the sale of the European business and the acquisition of Astria Therapeutics. The FDA approval for ORLADEYO in younger pediatric patients expands its market, and the positive interim Phase 3 data for navenibart further strengthens the long-term growth trajectory in the HAE market. The maintained 2026 revenue guidance indicates continued confidence. These factors collectively present a very strong outlook for the company.

Keywords

BioCryst Pharmaceuticals, BCRX, ORLADEYO, Hereditary Angioedema, HAE, Navenibart, Astria Therapeutics, Biotechnology, Rare Diseases, Financial Results, FDA Approval, Plasma Kallikrein Inhibitor, BCX17725, Netherton Syndrome, Pharmaceuticals, Drug Development, Clinical Trials